Biomics Biotechnologies, China, founded in February 2006, is on road to be counted as one of Asia's leading RNA interference (RNAi) therapeutical technology company. The company has a portfolio of more than 40 patents and patent applications to protect its technologies and products.

"There exists a natural drug-making machine, RNAi, in all human cells, which was discovered by 2006 Nobel Prize winners in the US. I wished to turn RNAi mechanism into real therapeutics to cure many incurable diseases," says Dr York Zhu, who founded the company, explaining why he chose to focus on RNAi technology.

Dr York Zhu, who returned home to China from the US, to set up the company, raised initial funding from venture capitalists. The company today has 100 employees and an industrial land of 100 acre at Nantong in Jiangsu province of China where a 10,000 square meter pilot facility has been constructed and is in use since 2007.

Biomics has recognized collaborations as one of the ways of growth, and thus partnered with several companies in Asia Pacific to provide services. It has collaborated with Benitec, a public Australian RNAi therapeutics research company, with focus on developing anti-HBV siRNA therapeutic. The two companies in 2011 announced the success of the first stage of anti-viral program to develop an RNAi-based therapy against Hepatitis B virus (HBV). The companies have proceeded to the next stage, which is designed to develop an RNAi therapeutic to the point of pre-clinical studies in vivo.

Collaboration with Zetiq, an Israeli company, concentrates on development of a novel cervical cancer diagnostic kit, CellDetect. Biomics has exclusive rights to distribute, market and sell the CellDetect cervical cancer diagnosis technology in China. The CellDetect technology can differentiate by color and morphology between normal cells and a wide range of cancer conditions.